Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Milestone Pharmaceuticals Inc(MIST)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for MIST
09/15/2026: MIST (1-star) is currently NOT-A-BUY. Pass it for now.
Milestone Pharmaceuticals is a clinical-stage biotechnology company developing Etripamil, a novel, self-administered therapy for cardiovascular conditions like PSVT. Its main strength lies in its proprietary drug-delivery technology, which aims to provide patients with an alternative to emergency room treatments. The primary investment opportunity centers on the successful commercial launch and label expansion of Etripamil. However, the company faces significant risks, including regulatory uncertainties, high cash burn, and the challenges of competing against established standard-of-care practices. Milestone best suits risk-tolerant investors seeking exposure to drug development milestones; it is not suitable for income-seeking investors, as it pays no dividends.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers potential for high growth contingent on regulatory approval and commercial success. |
| Momentum investor | Mixed fit | Momentum is highly dependent on binary clinical and regulatory events that cause periodic price volatility. |
| Value investor | Weak fit | Milestone lacks the traditional earnings or cash flow metrics typically used by value investors to assess valuation. |
| Dividend investor | Weak fit | The company does not pay dividends and retains all capital for business development. |
| Low-risk investor | Weak fit | The speculative nature of drug development carries high risks and significant price volatility. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage biotech stocks are susceptible to sharp price swings based on news and trial outcomes. |
| Valuation risk | Medium / high | Valuation is speculative and highly dependent on future successful product commercialization. |
| Competition risk (traditional cardiovascular care) | Medium | Established alternatives and standard-of-care practices provide significant hurdles to market adoption. |
| Business quality | Medium | The business relies heavily on the clinical and commercial success of a singular technology platform. |
| Dividend income | Low / none | Investors should not expect income as all resources are dedicated to product development. |
| Execution risk | High | Successfully navigating regulatory pathways and commercializing a new drug is complex and uncertain. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Highly Choppy
The stock has experienced frequent, large price swings that make its near-term movement less predictable.
Analysis of Past Performance
Type Stock | Historic Profit -63.56% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 115.50M USD | Price to earnings Ratio - | 1Y Target Price 5.86 |
Price to earnings Ratio - | 1Y Target Price 5.86 | ||
Volume (30-day avg) 1.7M shares | Beta 0.98 | 52 Weeks Range 0.90 - 3.06 | Updated Date 09/16/2026 |
52 Weeks Range 0.90 - 3.06 | Updated Date 09/16/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.64 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Cardiovascular Drug Development | Future sales of Etripamil and potential pipeline assets. | The company currently spends money to develop drugs and aims to generate future revenue through commercial sales. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 7.66M | Price to Sales(TTM) 49.29 |
Enterprise Value 7.66M | Price to Sales(TTM) 49.29 | ||
Enterprise Value to Revenue 3.82 | Enterprise Value to EBITDA -1.43 | Shares Outstanding 124.50M | Shares Floating 106.47M |
Shares Outstanding 124.50M | Shares Floating 106.47M | ||
Percent Insiders 0.7 | Percent Institutions 50.57 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Milestone Pharmaceuticals Inc
Exchange NASDAQ | Headquarters Montreal, QC, Canada | ||
IPO Launch date 2019-05-09 | CEO, President & Executive Director Mr. Joseph G. Oliveto M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 38 | Website https://www.milestonepharma.com |
Full time employees 38 | Website https://www.milestonepharma.com | ||
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The company is also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate (AFib-RVR). It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.